keyboard_arrow_up

Acute Coronary Syndrome Market - Current and Future Players

“PharmaPoint: Acute Coronary Syndrome – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing ACS Market. The report identifies and analyses the key companies shaping and driving the global ACS market. The report provides insight into the competitive ACS landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Complete report available @ http://www.rnrmarketresearch.com/pharmapoint-acute-coronary-syndrome-current-and-future-players-market-report.html .

Scope

  • - Investigation of current and future market competition for ACS
  • - Competitor assessment
  • - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • - Strategic assessment of ACS sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • - Gain a high level view of the trends shaping and driving ACS market
  • - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • - Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • - What’s the next big thing in the global ACS market landscape? Identify, understand and capitalize

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=214289 .

List of Tables
Table 1: Global Sales Forecasts ($bn) for ACS, 2013-2023 19
Table 2: Acute Coronary Syndrome Market - Drivers and Barriers, 2014 26
Table 3: Key Companies in the Acute Coronary Syndrome Market, 2014 37
Table 4: Amgen's Acute Coronary Syndrome Portfolio Assessment, 2014 42
Table 5: Amgen SWOT Analysis, 2014 42
Table 6: AstraZeneca's Acute Coronary Syndrome Portfolio Assessment, 2014 44
Table 7: AstraZeneca SWOT Analysis, 2014 45
Table 8: Bristol-Myers Squibb's Acute Coronary Syndrome Portfolio Assessment, 2014 47
Table 9: Bristol-Myers Squibb SWOT Analysis, 2014 47
Table 10: Daiichi Sankyo's Acute Coronary Syndrome Portfolio Assessment, 2014 49
Table 11: Daiichi Sankyo SWOT Analysis, 2014 50
Table 12: Eli Lilly's Acute Coronary Syndrome Portfolio Assessment, 2014 52
Table 13: Eli Lilly SWOT Analysis, 2014 52
Table 14: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2014 54
Table 15: GlaxoSmithKline SWOT Analysis, 2014 54
Table 16: Janssen's Acute Coronary Syndrome Portfolio Assessment, 2014 56
Table 17: Janssen SWOT Analysis, 2014 56
Table 18: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2014 59
Table 19: The Medicines Company SWOT Analysis, 2014 60
Table 20: Merck's Acute Coronary Syndrome Portfolio Assessment, 2014 62
Table 21: Merck SWOT Analysis, 2014 63
Table 22: Pfizer's Acute Coronary Syndrome Portfolio Assessment, 2014 65
Table 23: Pfizer SWOT Analysis, 2014 66
Table 24: Sanofi's Acute Coronary Syndrome Portfolio Assessment, 2014 68
Table 25: Sanofi SWOT Analysis, 2014 69
Table 26: Price Sources and Calculations, by Country 79
Table 27: Physicians Surveyed, By Country 83